Proxygen: $0.5B deal with Merck

Vienna-based BioTech Proxygen has signed a multi-year research and licensing agreement with Merck. Worth $554 million. Proxygen is a spin-off of CeMM (Research Center for Molecular Medicine of the Austrian Academy of Sciences). It develops compounds that use the cellular ...

UriSalt declares bankruptcy

Founded in 2018, startup UriSalt had developed a way to determine sodium balance via disposable urine strips and had been at A1 Startup Campus since 2020. Typically, a lab test and invasive blood test is required to determine a person's ...